2026 ICD-10-CM Diagnosis Code D45Polycythemia vera

ICD-10-CM CodesC00–D49D37-D48D45

ICD-10-CM D45
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

D45 is a billable ICD-10-CM diagnosis code for polycythemia vera. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 820 through 825, 840 through 842. Coders also document this condition as chorea due to polycythemia rubra vera. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Neoplasms of unspecified nature or uncertain behavior.

For Medicare Advantage risk adjustment, D45 maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors) under the V28 model, adding a risk factor of about 0.186 for a community, non-dual, aged beneficiary in payment year 2026.

Code Identity

ICD-10-CM Code
D45
Billable Status
Yes — Valid for Submission
Code Describes
Polycythemia vera
Short Description
Polycythemia vera
Same as the full description in the CMS dataset.
Chapter
D37-D48
Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes

Code Classification

ChapterC00–D49Neoplasms
SectionD37-D48Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes
CategoryD45Polycythemia vera
This CodeD45Polycythemia vera

Medicare Risk Adjustment (HCC)Billing

D45 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2026.

CMS-HCC V28 Category (Payment Model)
HCC 23— Prostate, Breast, and Other Cancers and Tumors
Payment HCC · PY 2026 one of 234 ICD-10-CM codes in this category
Risk Adjustment Factor (RAF) Weight
+0.186
community, non-dual, aged · ranges 0.186–0.237 across segments
Hierarchy
Superseded by HCC 17, HCC 18, HCC 19, HCC 20, HCC 21, and HCC 22
a more severe related category takes the payment when both are reported
Prior Model (CMS-HCC V24)
HCC 48
V24 retired V28 pays 100% of MA risk scores since PY 2026
Other CMS Models
PACE (CMS-HCC V22): HCC 48 · ESRD (V21): HCC 48 · ESRD (V24): HCC 48
ESRD V21 weights: 0.059 dialysis, 0.173–0.234 functioning graft · ESRD V24 weights: 0.063 dialysis, 0.192–0.358 functioning graft
Part D (RxHCC)
RxHCC 21 — Lymphomas and Other Hematologic Cancers
also risk-adjusts in the Part D prescription drug model (V08)

Source: CMS Payment Year 2026 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Chorea due to polycythemia rubra vera
  • Erythrocytosis due to polycythemia vera
  • Myelofibrosis
  • Myelofibrosis due to another disorder
  • Polycythemia vera
  • Polycythemia vera in remission
  • Post-polycythemia vera myelofibrosis

Tabular List NotesGuidance

Coding notes and annotation back-references applicable to this code.

Type 1 Excludes

  • familial polycythemia D75.0
  • secondary polycythemia D75.1

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO072
Neoplasms of unspecified nature or uncertain behavior
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Polycythemia Vera

    a myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. hematopoiesis is also reactive in extramedullary sites (liver and spleen). in time myelofibrosis occurs.

Patient EducationClinical

Bone Marrow Diseases

Bone marrow is the spongy tissue inside some of your bones, such as your hip and thigh bones. It contains stem cells. The stem cells can develop into the red blood cells that carry oxygen through your body, the white blood cells that fight infections, and the platelets that help with blood clotting.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert D45 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
207.10 Chr erythrm w/o ach rmsn
Approximate The match is approximate rather than exact.
ICD-9-CM
207.11 Chr erythrm w remision
Approximate The match is approximate rather than exact.
ICD-9-CM
207.12 Chr erythrmia in relapse
Approximate The match is approximate rather than exact.
ICD-9-CM
238.4 Polycythemia vera
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About D45Overview

What is the ICD-10 code for polycythemia vera?

The ICD-10-CM code for polycythemia vera is D45. It is billable on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

Is D45 (Polycythemia vera) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report polycythemia vera on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does D45 group to?

When polycythemia vera is the principal diagnosis on an inpatient stay, it groups to MS-DRG 820, 821, 822, 823, 824, 825, 840, 841, 842, with relative weights from 1.0104 to 5.8648 depending on complications. Higher weights mean higher Medicare reimbursement.

What is the ICD-9 equivalent of D45?

Under the General Equivalence Mappings, polycythemia vera converts to ICD-9-CM 207.10 (chr erythrm w/o ach rmsn), 207.11 (chr erythrm w remision), and 207.12 (chr erythrmia in relapse). The mapping is approximate, so confirm the match fits the documentation.

What HCC is D45?

D45 (polycythemia vera) maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors), commonly written as HCC 23, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2026. It mapped to HCC 48 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 21.

Does D45 risk-adjust for Medicare Advantage payment?

Yes. When documented and reported on a Medicare Advantage encounter, D45 adds a risk adjustment factor of about 0.186 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.186 to 0.237 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, HCC 20, HCC 21, and HCC 22) supersedes it when both are reported. See the full factor table on the HCC 23 category page.